Moraxella catarrhalis is an exclusively human pathogen and is a common cause of otitis media in infants and children, causing 15%-20% of acute otitis media episodes. M. catarrhalis causes an estimated 2-4 million exacerbations of chronic obstructive pulmonary disease in adults annually in the United States. M. catarrhalis resembles commensal Neisseria species in culture and, thus, may be overlooked in samples from the human respiratory tract. The prevalence of colonization of the upper respiratory tract is high in infants and children but decreases substantially in adulthood. Most strains produce blactamase and are thus resistant to ampicillin but susceptible to several classes of oral antimicrobial agents. Recent work has elucidated mechanisms of pathogenesis and focused on vaccine development to prevent otitis media in children and respiratory tract infections caused by M. catarrhalis in adults with chronic obstructive pulmonary disease.
. Bars represent the percentage of middle ear fluid samples that were positive by culture. Some cultures grew у1 species, which accounts for totals 1100%. The black portions of the bars represent samples that grew Moraxella catarrhalis in culture, the white portions represent samples that grew nontypeable Haemophilus influenzae in culture, and the gray portions represent samples that grew Streptococcus pneumoniae in culture.
Figure 2.
Gram-stained smear (original magnification, ϫ1000) of expectorated sputum from an adult experiencing an exacerbation of chronic obstructive pulmonary disease caused by Moraxella catarrhalis. Note the abundance of neutrophils, gram-negative diplococci as the exclusive bacterial form, and intracellular bacteria (arrows). dict etiology in an individual patient. Tympanocentesis is required to make an etiological diagnosis of otitis media, but this procedure is not performed routinely. Therefore, treatment of otitis media is generally empirical.
Recurrent otitis media and otitis media with effusion. Otitis media with effusion refers to the presence of middle ear fluid without clinical signs of acute otitis media. Children who have у4 episodes of acute otitis media in a year or who experience at least 8 months of middle ear effusion in a year are defined as otitis prone [11] . Otitis prone children may experience conductive hearing loss, with resultant delays in speech and language development [12] .
When middle ear fluid samples from children who have otitis media with effusion are analyzed using sensitive methods such as polymerase chain reaction, up to 80% contain bacterial DNA from H. influenzae, M. catarrhalis, or S. pneumoniae, suggesting that bacteria play a role in the disease [13] [14] [15] [16] . Indeed, M. catarrhalis DNA is detected in a larger proportion of cases of otitis media with effusion than of acute otitis media. Although the presence of bacterial DNA may indicate the presence of viable but nonculturable bacteria, the significance of these observations is not yet fully known.
The role of biofilms in otitis media has received an increasing amount of attention recently, particularly in the setting of recurrent otitis media and otitis media with effusion. A biofilm is a community of bacteria enveloped in a self-produced matrix that adheres to a surface. Bacteria in the form of biofilms are relatively resistant to antibiotics and to host immune mechanisms. Biofilms of M. catarrhalis are present in the middle ears of children with otitis media and may account, in part, for recurrent and chronic otitis media [17] . However, the role of biofilms in the pathogenesis of otitis media is not yet fully elucidated.
M. CATARRHALIS AND COPD
The course of COPD is characterized by intermittent worsening of symptoms, called exacerbations. Exacerbations are associated with lost work time, emergency room visits, hospital admissions, respiratory failure, and sometimes death. The best estimates indicate that approximately one-half of exacerbations are caused by bacterial infection, with the remainder being caused by viral infection and noninfectious causes [18] . The clinical features of an exacerbation due to M. catarrhalis are similar to those of exacerbations due to other pathogenic bacteria, including H. influenzae and S. pneumoniae. The cardinal symptoms of COPD exacerbations are increased sputum production, sputum purulence, and dyspnea, compared with baseline symptoms. Other features may include fever and fatigue. There is much variability in the combination of symptoms that occurs with each exacerbation. Examination of the chest usually reveals rhonchi and generalized decreased air entry. Localized crackles should prompt chest radiography to exclude pneumonia. A Gram-stained smear of sputum reveals neutrophils and abundant gram-negative diplococci, including intracellular bacteria (figure 2).
Point-prevalence studies suggest that M. catarrhalis is an important cause of exacerbations of COPD [19] [20] [21] . However, because M. catarrhalis is isolated from the sputum of adults with COPD even during clinically stable periods, one cannot conclude that the presence of the bacterium in the sputum of an adult with an exacerbation of COPD indicates that M. catarrhalis is the cause of the exacerbation. Four main lines of [25, 26] Development of strain-specific protection following clearance [26] Development of new systemic and/or mucosal antibody responses following clearance [26, [29] [30] [31] [32] Increased airway inflammation in M. catarrhalis culture-positive exacerbation, compared with culture-negative exacerbation [27, 28] evidence support the conclusion that M. catarrhalis causes exacerbations of COPD. Lower respiratory tract bacteriology. Bacterial pathogens are present in the airways in concentrations associated with respiratory tract infection in approximately one-half of adults with exacerbations of COPD when the distal airways are sampled using bronchoscopy with the protected specimen brush or transtracheal aspiration. M. catarrhalis is among the bacterial species that are isolated from the distal airways in such studies [20, [22] [23] [24] .
Acquisition of new strains. Molecular typing of longitudinally collected strains reveals that, rather than increases in the numbers of a persistent colonizing strain, the acquisition of a new bacterial pathogen plays a central role in the pathogenesis of bacterial exacerbations [25] . In approximately onehalf of the instances when an adult with COPD acquires a new strain of M. catarrhalis, clinical symptoms of exacerbation are observed [25, 26] . This rate is similar to that observed for exacerbations after acquisition of new strains of H. influenzae and Pseudomonas aeruginosa and somewhat higher than that observed for S. pneumoniae.
Immune responses. Adults with COPD who experience exacerbations associated with acquisition of new strains of M. catarrhalis develop immune responses after infection. In a longitudinal study, we examined monthly sputum cultures from 104 patients with COPD over a period of 81 months and demonstrated that, of the 50 patients who acquired M catarrhalis, 72% generated new systemic or mucosal antibody responses to their homologous isolates [26] . Clearance of the strain from the respiratory tract was associated with strain-specific protection.
Airway inflammation. Sputum from patients with exacerbations associated with acquisition of a new strain of M. catarrhalis have elevated markers of airway inflammation compared with exacerbations in which no bacterial pathogen is isolated [27, 28] . Because the severity of clinical symptoms of exacerbations closely parallels levels of airway inflammation, these observations strongly implicate M. catarrhalis in the etiology of exacerbations, specifically after acquisition of a new strain.
Prevalence of M. catarrhalis as a cause of exacerbations. As outlined above, results of studies that analyzed lower airway bacteriology, acquisition of new strains, immune responses, and host inflammatory responses represent independent lines of evidence suggesting that M. catarrhalis causes exacerbations of COPD (table 1) . On the basis of the results of an ongoing prospective study, M. catarrhalis is the second most common bacterial cause of exacerbations after H. influenzae (figure 3). The best estimate is that M catarrhalis causes ∼10% of exacerbations of COPD, accounting for 2-4 million exacerbations annually in the United States [26] .
Chronic colonization of the airways in persons with COPD.
The respiratory tract of healthy people is sterile below the vocal cords. However, the lower airways of some adults with COPD are colonized by bacteria as a result of impaired mucociliary clearance, even in a clinically stable state. Carefully performed point-prevalence studies that have used bronchoscopy and a protected specimen brush to obtain uncontaminated lower airway cultures have demonstrated that M. catarrhalis colonizes the lower respiratory tract in up to 2.5%-10% of adults with COPD while in a stable state [22, 33] . Bacteria in the airways slough highly inflammatory cell wall antigens into the airways, and this process contributes to the airway inflammation that is a hallmark of COPD.
OTHER INFECTIONS CAUSED BY M. CATARRHALIS
Sinusitis. Bacterial sinusitis occurs after a small percentage of viral upper respiratory tract infections. M. catarrhalis is responsible for ∼20% of cases of acute bacterial sinusitis in children and a smaller proportion of cases in adults [34] [35] [36] . Sinusitis due to M. catarrhalis is clinically indistinguishable from that caused by S. pneumoniae or H. influenzae.
Bacteremia, pneumonia, and other invasive infections. Pneumonia due to M. catarrhalis occurs infrequently but is well described in elderly persons, especially in those with underlying cardiopulmonary disease [37] . M. catarrhalis rarely causes bacteremic illness. A recent review identified only 72 reported cases [38] ; these cases included endocarditis, pneumonia with bacteremia, preseptal and periorbital cellulitis, neonatal meningitis, and septic arthritis. No clear association between M. catarrhalis infection and a particular immunodeficiency has been identified [39] .
EPIDEMIOLOGY AND DYNAMICS OF RESPIRATORY TRACT COLONIZATION
Children. M. catarrhalis is an exclusively human pathogen with an ecological niche in the human respiratory tract. The prevalence of colonization of the upper respiratory tract is highly dependent on age. Whereas the rate of colonization among adults is low (1%-5%), nasopharyngeal colonization is quite common through infancy [40, 41] . A substantial variation in rates of colonization is observed in different geographic regions. One study in Buffalo, New York, demonstrated that 66% of infants were colonized at least once during the first year of life, whereas a similar study in Goteberg, Sweden, demonstrated colonization at one-half of that rate [42, 43] . Active turnover of different strains is observed. In a study of rural aboriginal infants near Darwin, Australia, 100% of infants were colonized with M. catarrhalis by the age of 3 months [44] . Several factors-including living conditions, hygiene, environmental factors (e.g., household smoking), genetics of the population, and others-likely account for differences in colonization rates. The pathogenesis of otitis media involves migration of bacterial pathogens from the nasopharynx to the middle ear via the Eustachian tube; therefore, patterns of nasopharyngeal colonization are important determinants of otitis media.
A change in patterns of nasopharyngeal colonization is occurring in countries where pneumococcal conjugate vaccines are used widely. Colonization by vaccine serotypes of pneumococcus is decreasing, and colonization by the nonvaccine pneumococcal serotypes H. influenzae and M. catarrhalis is increasing, resulting in a shift in the pathogens that cause otitis media [45, 46] . Revai et al. [47] demonstrated a significantly greater prevalence of M. catarrhalis in the nasopharynx during episodes of otitis media in children who had received the vaccine, compared with the prevalence among episodes that occurred before introduction of the pneumococcal conjugate vaccine. Pneumococcal vaccination does not affect the genetic diversity of nasopharyngeal isolates of M. catarrhalis, suggesting that the increase in prevalence of colonization will translate to increased rates of otitis media [48] . Similar shifts are being observed among children and adults with sinusitis [36, 49] .
Adults with COPD. Although clinical trials demonstrate that M. catarrhalis is cultured frequently from adults with COPD, point-prevalence studies do not paint a full picture of the dynamics of acquisition, colonization, and clearance in the setting of COPD. Longitudinal analysis, including the molecular typing of strains, demonstrates that once a strain is cleared, protection from reacquisition of the same strain is observed [26] . The median duration of carriage of a strain was relatively short (∼1 month). This pattern of colonization is quite distinct from that of H. influenzae, in which a subset of strains causes persistent colonization for months to years in adults with COPD.
Nosocomial transmission. M. catarrhalis is transmitted among patients in hospitals, particularly in multiple-bed wards and during winter months [50, 51] . Clusters of M. catarrhalis respiratory tract infections have been reported in hospital units, but one must be cautious in concluding that the bacterium is the cause of infection when it is isolated [52] [53] [54] .
MICROBIOLOGICAL DIAGNOSIS
M. catarrhalis is a gram-negative diplococcus that produces nonhemolytic, round, opaque colonies on blood agar. Colonies of M. catarrhalis resemble commensal Neisseria that are present in the normal human upper airway flora. M. catarrhalis colonies can be slid along the agar surface without disruption; this is termed the "hockey puck sign." In addition, after 48 h of growth M. catarrhalis colonies tend to be larger than those of Neisseria and take on a pink color. The difficulty in distinguishing colonies of M. catarrhalis from those of Neisseria explains, in part, why M. catarrhalis has been overlooked as a respiratory tract Sensitive methods, such as polymerase chain reaction, to detect M. catarrhalis and other bacterial pathogens in respiratory secretions are in development. Indeed, M catarrhalis DNA in middle ear effusions can be detected by polymerase chain reaction in children with otitis media [13] [14] [15] 17] . The application of such sensitive assays are likely to contribute important new observations about the epidemiology and disease patterns of M. catarrhalis, but they are not yet commercially available.
PATHOGENESIS OF INFECTION
The pathogenesis of bacterial otitis media involves the migration of bacteria from the nasopharynx to the middle ear via the Eustachian tube, which is often precipitated by a preceding viral infection. The acquisition of a new strain of M. catarrhalis is a key element in the pathogenesis of exacerbations of COPD. Analysis of the genetic relationships among strains indicates that strains of M. catarrhalis differ with regard to virulence [55] [56] [57] . The species is composed of 2 distinct lineages; the seroresistant lineage appears to be more strongly associated with virulence [57] . Furthermore, the distribution of virulence-associated genotypes and phenotypes differs in strains found in children, compared with those found in adults [58] .
The recognition of M. catarrhalis as an important human pathogen has stimulated active investigation into the molecular mechanisms of pathogenesis, and some of these observations are highlighted briefly here. A critical initial step in colonization and infection is adherence to the respiratory tract epithelium. Table 2 lists the growing number of adhesins that have been identified in M. catarrhalis.
M. catarrhalis was previously thought to be an exclusively extracellular pathogen. However, M. catarrhalis invades multiple cell types, including bronchial epithelial cells, small airway epithelial cells, and type 2 alveolar cells [59] . Furthermore, M. catarrhalis is present intracellularly in human pharyngeal lymphoid tissue, providing a potential reservoir for persistence in the human respiratory tract [60] .
One mechanism that M. catarrhalis uses to subvert innate host immune responses is complement inactivation by multiple mechanisms that render strains of M. catarrhalis resistant to killing by human serum [61, 62] . Indeed, seroresistant strains may be more virulent [55, 57] .
M. catarrhalis forms biofilms in vitro and have been identified in middle ear samples obtained from children [17, 63] . The role of biofilms in the pathogenesis of otitis media is an area of active investigation. M. catarrhalis induces activation of the mitogen-activated protein kinase and nuclear factor-kB sig- naling systems in bronchial epithelial cells, with release of interleukin-8 and granulocyte-macrophage colony-stimulating factor from the cells [64] . Three serotypes of M. catarrhalis have been identified based on structural differences in lipooligosaccharide [65] . Serotype A is the predominant type among clinical isolates. The distribution of serotypes appears to differ by patient age, with isolates from adults having a somewhat greater proportion of serotype A, compared with those from children [58, 65] . Lipooligosaccharide is likely a key inducer of the host inflammatory response.
Animal models. Studies of the pathogenesis of and host response to M. catarrhalis infection have been limited by the absence of a good animal model of infection. M. catarrhalis does not readily infect or colonize a variety of laboratory animal species, consistent with the observation that M. catarrhalis is an exclusively human pathogen. The chinchilla model of otitis media that has yielded important observations in the case of S. pneumoniae and H. influenzae has not been useful in studying M. catarrhalis, because the organism is cleared readily from the middle ear of chinchillas and other animals. Chinchillas can be colonized in the nasopharynx for several weeks and, thus, may be useful for studies of colonization. A mouse pulmonary clearance model has been useful for assessing putative vaccine antigens (see the Status of Vaccine Development section).
TREATMENT CONSIDERATIONS
More than 90% of M. catarrhalis produce a b-lactamase and are, thus, resistant to ampicillin. Two types of b-lactamases have been identified, BRO-1 and BRO-2 [66] . After the rapid acquisition of b-lactamase in the 1970s and 1980s, the antimicrobial susceptibility of M. catarrhalis has remained relatively stable in surveys of worldwide collections of strains [67, 68] . Many infections due to M. catarrhalis can be treated with oral antibiotic therapy. Table 3 lists oral antibiotics that are active against M. catarrhalis. Treatment of otitis media in children and exacerbations of COPD in adults, the 2 most common infectious diseases caused by M catarrhalis, is generally empirical [1, 18] . Therefore, antimicrobial agents that are active against S. pneumoniae and H. influenzae, in addition to M. catarrhalis, are usually administered.
STATUS OF VACCINE DEVELOPMENT
A vaccine that would prevent otitis media in children, particularly otitis prone children, would have an enormous human and economic impact. Otitis media accounts for 113 million antibiotic prescriptions annually and approximately $6 billion in health care costs in the United States annually [1] . A recent clinical trial assessing a vaccine that is composed of pneumococcal polysaccharide of 11 capsular serotypes conjugated to protein D, a surface protein of H. influenzae, demonstrated partial protection against both pneumococcal and H. influenzae otitis media [69] . The demonstration of induction of a protective response against H. influenzae with a surface protein antigen represents proof of principle for the approach of using a surface protein of a nonencapsulated gram-negative bacterium as a vaccine antigen. A successful vaccine for otitis media should be directed toward preventing infection due to S. pneumoniae, H. influenzae, and M. catarrhalis. A second population that would benefit from a vaccine to prevent M. catarrhalis infections are adults with COPD.
An obstacle for the development of a vaccine against M. catarrhalis is the absence of a good animal model. The most widely used model for assessing M. catarrhalis vaccine antigens is the mouse pulmonary clearance model, which measures clearance of bacteria from the lungs following bacterial challenge directly into the airways. However, this model system does not simulate human respiratory tract infection, because animals do not show evidence of infection but rather clear M. catarrhalis in ∼24 h. The identification of a reliable correlate of protection from M. catarrhalis infection, such as an in vitro assay or an animal model, would facilitate vaccine development for M. catarrhalis.
The observation that patients with COPD appear to develop strain-specific protection after clearing M. catarrhalis supports the feasibility of inducing protective responses to M. catarrhalis [26] . The challenge is to design a vaccine that will induce such a protective response against all strains. An approach that has been taken by several research groups has been to identify and assess conserved surface molecules as vaccine antigens. The ideal vaccine antigen would be (1) present on the surface of all strains, (2) antigenically conserved among strains, (3) expressed during infection of the human host, (4) immunogenic in infants, and (5) capable of inducing a protective immune response. Recently, a genome-mining approach has identified additional vaccine antigens for M. catarrhalis [70] . Table 2 summarizes several potential vaccine antigens that are in various stages of development.
SUMMARY
M. catarrhalis is an exclusively human pathogen that may be overlooked in culture because of its phenotypic similarity to commensal Neisseria, which are part of the normal flora of the upper respiratory tract. Widespread administration of pneumococcal conjugate vaccines may be causing an increase in M. catarrhalis infections by altering patterns of nasopharyngeal colonization. M. catarrhalis causes 10%-20% of otitis media episodes in children and is the second most common cause of exacerbations of COPD in adults. The species is composed of 2 distinct genetic lineages that appear to differ with regard to virulence capabilities. A vaccine to prevent M. catarrhalis infections would have a substantial human and economic impact. Several potential vaccine antigens are in various stages of development.
